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Abstract: Endogenous neurogenesis in stroke is insufficient to 
replace the lost brain tissue, largely due to the lack of a proper 
biological structure  to let new cells dwell in the damaged area.  We 
hypothesized  that  scaffolds  made   of   hyaluronic   acid (HA) 
biomaterials (BM) could provide a suitable environment to home not 
only new neurons, but also vessels, glia and neurofila- ments. 
Further, the addition of exogenous cells, such as adipose stem cells 
(ASC) could increase this effect. Athymic mice were randomly 
assigned to a one of four group: stroke alone, stroke and 
implantation of BM, stroke and implantation of  BM  with ASC, and 
sham operated animals. Stroke model consisted of middle cerebral 
artery thrombosis with FeCl3. After 30 days, ani- mals underwent 
magnetic resonance imaging (MRI) and were 
sacrificed. Proliferation and neurogenesis increased at the sub- 
ventricular zone ipsilateral to the ventricle and neuroblasts, glial, and 
endothelial cells forming capillaries were seen  inside  the  BM. 
Those effects increased when ASC were added, while there was 
less inflammatory reaction. Three-dimensional scaffolds made of 
HA are able to home newly formed neurons, glia, and endothelial 
cells permitting the growth neurofilaments  inside them. The 
addition of ASC increase these effects and decrease the 
inflammatory reaction to the implant. © 2018 Wiley Periodicals, Inc. J 
Biomed Mater Res B Part B: 00B: 000–000, 2018. 
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INTRODUCTION 
In spite of the extensive pharmacological and neurorehabil- 
itation efforts made to recover the neurological deficits, stroke 
is still the main cause of disability in the occidental world. 
Ischemic stroke produces an area of necrosis (core zone) 
surrounded by a partially damaged zone (area of 
 
penumbra).1 Most of the therapeutic efforts up to now have 
been directed to reduce the extent and to improve the func- 
tional recovery of the penumbra zone.2 However,  there  is not 
a reliable way to repair the lost tissue.3 
After an experimental stroke, there is an increase of the 
neurogenesis at the subventricular zone (SVZ), a main adult 
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neurogenic niche, especially at the ipsilateral hemisphere, and 
new neurons and supporting cells migrate massively to the 
area of infarction.4 However, most of these cells disap- pear 
from the lesion by the 5th week.5 We hypothesize that the 
main reason for this is the lack of a proper substrate where 
the cells can survive, reconnect, and recover their function due 
to the generation of an adverse environment after the stroke6,7 
and/or to the absence of a material scaf- fold upon which new 
neurons and supporting structures  such as glia and vessels 
can grow and organize. 
The   use   of   three-dimensional   (3D)   biomaterials (BM) 
could provide a proper scaffold for these newly formed cells, 
permitting the organization of neural tissue with neu- rons, 
glial cells and vessels, guiding the neurite prolonga- tions and 
providing a more appropriate environment for neural 
regeneration.8–12 Among the multiple available bio- 
compatible    materials,    we    chose     hyaluronic     acid   (HA) 
because this is an already used BM in other clinical 
applications and it is simple to make and manipulate.13,14 
Furthermore, mesenchymal stem cells have been shown to 
home endogenous stem cells close  to  the infarcted area,  as 
well as to increase neovascularization at the  same  site and 
proliferation at the SVZ, and also to diminish the inflam- 
matory reaction at the lesion site.15–18 We hypothesized that 
the addition of mesenchymal stem cells to the BM would 
increase their capacity to home endogenous stem cells, and 
possibly to facilitate their entry into the BM by inhibiting the 
scar reaction around the scaffold.19,20 Among the mesenchy- 
mal cells available, we have chosen adipose stem  cells  (ASCs) 
because of practical reasons: they are easily handled, they are 
widely available from lipoaspirate donation for allo- genic use 
and our group has already shown their potential benefits for 
clinical application in stroke.21–23 
The objectives of this study were to determine if 3D scaf- 
folds of hyaluronic acid (HA) implanted at the penumbra zone 
of a vascular stroke lesion in rats were able to home local 
neural and endothelial cells and neurites, and also to compare 
these homing capacities between BM co-grafted with adult 
human ASC and BM without them, as well as to study the host’s 
reaction to the  implant in both cases, both  in terms of glial 
scar formation and neurogenetic production. 
Also, if this represents a viable and safe method in order to 
transfer this to the clinical practice. 
 
MATERIALS AND METHODS 
Preparation of HA porous scaffolds 
HA porous scaffolds were made as described Rodríguez- Pérez 
et al.24 Briefly, HA sodium salt from Streptococcus  equii (1.5–
1.8 MDa; Sigma-Aldrich) was dissolved overnight to a 5% 
(w/v) in 0.2 M sodium hydroxide (NaOH, Scharlab). Then, 
divinyl sulfone (DVS, Sigma-Aldrich) was added as a 
crosslinker in a 9:10 DVS:HA monomeric units molar ratio. 
Once homogenized for 10 s more, the solution was vaccuum- 
injected into molds made from sintered beads of poly (ethyl 
methacrylate; PEMA, Elvacite® 2043, Lucite International, 
Inc.). These beads  had  a  diameter  of  between  180  and 250 
μm. The crosslinking reaction of HA with DVS was left   to 
complete for an hour and a half. 
After that, PEMA beads template was removed by leach- 
ing reflux in a Soxhlet extraction apparatus using boiling eth- 
anol as solvent for 48 h. Afterwards, HA scaffolds were 
immersed in distilled water for 3 h, frozen at −20○C for another 
2 h and then lyophilized. All scaffolds were cut into cylinders 
with 0.8 mm diameter and 8 mm of length. Other tests were 
carried out to warrant the absence of pyrogens or endotoxins, 
to guarantee biomaterial’s innocuity. 
 
Analysis of 3D structure of biomaterials 
The HA scaffolds, previously sterilized by chemical means, 
were analyzed by scanning electron microscopy to analyze the 
3D configuration of the scaffold, ensuring that pores are 
between 300 and 150 um in diameter were present, so that 
ASC can easily enter the BM. For this purpose, they were 
processed in a critical dot dryer, followed by gold–palladium 
shading to provide electroconductivity to the sample and 
analyzed in a scanning electron microscope JEOL JSM 5410 
with a voltage of 10 KV at different magnitudes (Figure 1). 
 
Adipose stem cells 
Adipose tissue samples were obtained from donors during 
routine abdominoplasty following informed patient consent 




FIGURE 1. Scanning electronic micrographs showing porous scaffolds made of hyaluronic acid at  different  magnifications  (A–D).  A–C:  shows images 
of the biomaterial and the characteristics of the scaffolding and D–E: images of ASC cells colonizing the scaffold. Scale Bar A: 500 μm, B: 300 μm, C: 




Ethics Committee on Biomedical Research. The adipose tis- 
sue was transported in sterile bottles and immediately pro- 
cessed to obtain the ASC and process under GMP conditions 
(Histocell, S.L., Bilbao, Spain). Phenotype characteristics, 
clonic capacity and stem cell differentiation biomarkers as 
described by Gomez-Pinedo et al.23 
The ASC were maintained until phase 7 in culture on the 
material to perform studies of telomerase and C-myc expres- 
sion, to guarantee the stability of the cultured cells on the 
biomaterial. Before use, we proceeded to carry out the 
immunophenotype of the ASC cells to be considered mesen- 
chymal stem cells and useful for our purpose. 
 
Scaffold preloading 
ASC were used in the fourth cell phase. Cells were resus- 
pended in culture medium at a concentration of 5x104/4 μL. 
This concentration was inoculated inside the HA biomaterial 
(dimensions for the preclinical study of 1 x 1 mm) with the 
help of a Hamilton® microsyringe. The biomaterials inocu- 
lated with ASC were maintained in 24-well plates with the 
culture medium composed of DMEM-Glutamax + Antibiotic / 
10%  FBS  and  incubated  at  37○C/5%  CO2  for  72  h,  for 
subsequent implant in the model of athymic nude mice [Figure 
1(D–E)]. 
 
FeCl3 thrombosis model 
Nude-Foxn1NU/nu (dEnvigo -Harlan Laboratories) adult male 
mice were used for the experiments. At 7 weeks of age were 
 
housed in a temperature-controlled room with access to food 
and water ad libitum. They were kept in  individual  cages and 
under standard conditions in the animal facilities of the 
Hospital Clínico San Carlos. All procedures were carried out 
under animal welfare regulations in accordance with EC 
Council Directive November 24, 1986 and approved by the 
local ethics committee. 
Mice were anesthetized with 80–100 mg/kg ketamine and 
10 mg/kg xylazine. A small craniotomy was performed  to 
access the middle cerebral artery. For  the  formation  of the 
ischemia model, a FeCl3 solution (20%) was applied to the 
surface of the artery for 1 min. In the control group (sham) 
0.9% of saline solution was used.15,16 
 
Experimental and control groups 
Four groups were defined: Stroke (mice subjected to the 
stroke model), Stroke+BM (mice subjected to the stroke model 
to whom HA biomaterials alone  were  implanted  at the core 
zone), Stroke+BM+ASC (mice subjected  to  the stroke model 
to whom HA biomaterials co-grafted with ASC were implanted 
at the core zone) and sham (animals under- going the 
operation for the stroke model except the applica- tion of the 
thrombotic FeCl3 solution). Six animals were assigned 
randomly to each group. 
Seven days after the ischemic procedure, animals belong- 
ing to groups Stroke+BM and Stroke+BM+ASC were again 
anesthetized and the wound reopened. A burr hole was per- 




FIGURE 2. Magnetic resonance imaging demonstrating the infarcted area in the control group (only stroke) and the implanted groups. In the latter, 




FIGURE 3. Analysis of the glial scar. Representative immunohistochemical image showing glial fibrillary acidic protein (GFAP), (A) stroke; (B) stroke 
+BM; (C) stroke+BM+ASC; (D) The graph shows that in the group of animals with stroke, in which ASC were administered in biomaterials, they showed 
less expression of the GFAP, in the other two groups (stroke and stroke+BM) the expression of GFAP was significantly higher (**p < 0.05 and *p < 
0.01) Scale Bar: 100 μm. 
 
 
at the same coronal plane at which the occluded MCA branch 
was located. A cannula was inserted to implant the biomate- 
rials (with or without ASC) at a depth of 13 mm from the dural 
plane. (Supporting Information Figure 2). 
 
Magnetic resonance imaging 
The day of the sacrifice, the mice were anesthetized with iso- 
flurane 1.5–2% to obtain a brain MRI. All the MRI experiments 
were performed on a BIOSPEC BMT 47/40 (Bruker, Ettlingen, 
Germany)   spectrometer   operating   a  4.7  T,  equipped   with a 
11.2   cm   actively   shielded   gradient   system,   capable   of  200 
mT/m gradient strength and 80 μs of rise time. During the MRI 
procedure, the animals were kept at 37○C and a MR com- patible  
respiration sensor  was used to control the animals. The 
MRI experiments consisted of three-dimensional T2WI, a series 
of DWI to calculate the ADC maps and a series of PWI to calcu- 
late CBF maps. A 7-cm birdcage radiofrequency coil was used for 
transmission and reception. Image analysis was performed using 
ParaVision 3.0.1 (Bruker, Ettlingen, Germany). This calcu- lation 
was carried out using MATLAB 7.3 (MathWorks, Inc., Natick, MA). 
 
BrdU administration. The BrdU is an analog of the thymi- dine 
that the cell incorporates in the cellular cycle when entering 
into cellular division. Two hours before the sacrifice of the 
animals an intraperitoneal pulse of BrdU (60 mg/kg, 
 
Sigma-Aldrich) dissolved in physiological saline was adminis- 
trated to evaluate the proliferative activity of the endoge- nous 
stem cells in the SVZ, as well as implanted ASC cells.23 
At 37 days after stroke surgery, mice in each group were 
anesthetized with a dose of pentobarbital (60 mg/kg) and 
fentanyl (0.3 mg/kg) for subsequent intracardiac infusion 
with 0.9% solution Saline followed by 4% buffered parafor- 
maldehyde (0.1 M phosphate buffer). After perfusion, the 
brain was removed and washed with 0.1 M PB and cryopro- 
tected by immersion in 30% sucrose. The cuts were per- 
formed in a cryostat (model Micron 1800) at 50 microns thick 
containing the infarct area and  the  biomaterial  implant area. 
 
Histochemistry and immunofluorescence analysis 
The sections were washed with PBS, permeabilized with 0.1% 
Triton X-100 and blocked with 10% normal goat  serum. The 
following primary antibodies were then applied overnight at 
4○C: anti-HuNu (Millipore, human cells); GFAP (Dako 
Cytomation, astrocytes); Anti-CD31 (Abcam, newly formed 
endothelium); Anti-NueN (Millipore, neurons); Anti- DCX 
(Santacruz, neuroblasts); Anti-BrdU (Millipore, thymi- dine 
analogue); Anti-NF 160 and anti-NF 200 (Millipore, 
neurofilaments). Subsequently the samples were washed in 
PBS  three  times  for  subsequent   incubation   in   Alexa   488, 









TABLE I. Counting of Immature (NF 160 kD) and Mature 
(NF 200 kD) Neurofilaments Found in the Ischemic Zone in 
Stroke Controls, Stroke Animals After Placement of 
Biomateriales, and After Placement of Biomaterials with ASC 
(Units: Neurofilaments Per mm3) 
 
 
NF in the Ischemic Zone NF Into Biomaterial 
 
by the Bonferroni post hoc multiple comparisons test was used 
to draw comparisons between three groups. We used the 
program SPSS Statistics 20.0. For the graphical represen- 
tation of results, the Prism v 5.0 Graph Pad program was used. 
All data are expressed as mean standard error. The graphs of 
the results were performed using the same pro- 
Group    
NF 160 kD NF 200 kD NF 160 kD NF 200 kD 
gram. The criterion for statistical significance was p < 0.05. 
 
 
Stroke 9.3 T 6.7 2.1 T 1.9 – – 
Stroke+ASCs – – 36.2 T 17.9   12.6 T 9.4 
Stroke+BM+ASC – – 89.7 T 13.2   20.4 T 3.7 
Volume analyzed 0.69 mm3. 
 
antibodies, DAPI-contracted and mounted with the Fluorsave 
reagent (Calbiochem). Immunofluorescence images were 
obtained with the Olympus AF2000 confocal microscope. 
The quantitative study both at the SVZ and at the areas 
around the biomaterial consisted in the analysis of 10 differ- 
ent fields for each of the antibodies studied (BrdU, DCX, and 
GFAP) and the result was the average of 10 determinations. 
Within the BM, a volumetric analysis was performed using 
confocal microscopy of 12 optical segments 800 nm thick. 
The NF were counted in four optical planes by confocal 
microscopy in z projection. In cases where the unit of mea- 
surement was the observed mark quantity per field (Optical 
Density, DO), the software program Image J, v1.46r of the 
National Institutes of Health was used for its calculation. 
To estimate the DCX/DAPI index, DAPI-positive and DCX- 
positive cells were quantified in an area of 300 microns from 
the ischemic border region at the per-infarct zone. This esti- 
mation consists in the number of DCX+ cells divided per the 
total amount of cells (counted by their nuclei, which is stained 





Results are reported as the meanSD. Differences between 
means were determined by Student’s t test, with p < 0.05 
considered significant. One-way analysis of variance followed 
 
RESULTS 
After 72 h of incubation, cells were easily inserted into the 
scaffolds, and they were adhered to the walls  of the same in  a 
homogeneous way (Figure 1). Karyotype and phenotype did 
not show any alteration. 
The application of FeCl3 induced a limited and constant 
brain infarction located at the left parietotemporal cortex 
(Supporting Information Figure 1). Neurological deficits 
appearared 4 h after the surgery, as forelimb flexion, resis- 
tance to lateral push and circling behavior; but all animals 
returned to a normal neurological examination 12 h later. 
Animals did not show any further neurological alteration 
after the implant of the biomaterials, without inducing or 
inciting fever or implant rejection, suggesting the absence of 
pyrogenic elements. Magnetic resonance imaging showed that 
the implanted biomaterials were fully integrated  into the host 
tissue and reduced the cavitation provoked by  stroke in 
control animals. The reduction was more evident when ASC 
were added to the biomaterials (Figure 2). 
After stroke, there was an astrocytic reaction around the 
infarcted area. The astrocytic reaction to the biomaterial was 
not intense (similar to the one produced with stroke alone), 
but it was much less to the biomaterials precharged  with ASC, 
as we show in Figure 3 (Sham: 0.341 0.028  Stroke: 1.780 
0.106; Stroke+BM: 1.681 0.066; Stroke+BM+ASC: 
0.935 0.0868). 
Neurofilaments were scarcely seen at the infarcted area  in 
control animals, but they were found within the biomate- rials. 
After 30 days of scaffold implantation (with or without ASC) 
more neurofilaments, both immature (160 kD) and mature 





FIGURE 4. Immunohistochemical image showing the neurofilaments found inside the biomaterial+ASC 30 days after implantation. (HA: hyaluronic  














FIGURE 5. Immunohystochemical image showing implanted  biomate- rials 
plus ASC, showing CD31 positive cells inside, forming vessel-like 
structures. Scale Bar: 50 μm. 
 
 
than in the periphery of the  lesion  or  in  the  controls  (Table 
I). 
More neurofilaments  were  seen  in  the  biomaterial  plus 
ASC than in the one without them. Most of the neurofi- laments   
were   immature   (160   kD)   (Stroke:   9.3         6.7; 
Stroke+BM:   36.2         17.9;   Stroke+BM+ASC:   89.7        13.2; 
Table I and Figure 3), but mature neurofilaments (200 kD) 
were  also  seen  (Stroke:  2.1  T 1.9;  Stroke+BM:  12.6  T 9.4; 
Stroke+BM+ASC: 20.4 3.7, data expressed in NF into bio- 
material; Table I and Figure 4). 
CD31 positive cells were seen inside  the  implants (Figure 
5), but not in the infarcted area in control animals. Some of 
them were organized in tubule-like structures, resembling 
vessels. Also, more CD31 positive cells were seen inside the 
biomaterials pre-charged with ASC. 
There was a proliferative reaction at the SVZ after the stroke, 
in  the  number  of  BrdU  (Sham:  122        8; Stroke:  174        16; 
Stroke+BM: 241      11; Stroke+BM+ASC: 305       26) DCX (Sham: 
0.51         0.07;   Stroke:   0.94         0.08;   Stroke+BM:   1.52    0.09; 
Stroke+BM+ASC: 1.83 0.12) positive cells. The implantation of 
biomaterials increased this reaction. The preloaded cells (ASC) 
increased even further this effect (Figure 6). 
Newly formed neurons showing DCX were not seen inside the 
infarcted areas in control animals, although some of them were 
seen in the vicinity of the core zone. More cells were seen in the 
vicinity of the scaffold alone and even more around the 
biomaterials plus ASC. Inside the biomaterials we found some 
newly formed neuroblasts, and this number increased when  ASC  
were  co-grafted  (Stroke:  0.032 0.0082;   Stroke+BM: 0.061 
0.0096; Stroke+BM+ASC: 0.096 0.0169; Figure 7). 
Neither HuNu positive cells, not teratomas or any other 
neoplasic formation were found inside the biomaterials or  in the 




Here, we show that the implant of biomaterials made of HA at 
the core of a brain stroke lesion permits the migration of 
endogenous new neurons, glia, and endothelial cells, and the 




FIGURE 6. Immunohistochemical image showing cell proliferation at the SVZ. A–E: Immunostaining against BrdU. F–J: Immunostaing against dou- 
blecortin (DCX) with higher expression of DCX in the SVZ in the experimental group with biomaterials plus ASC. The images correspond the sham 
group (A and F), stroke (B and G), stroke plus biomaterials (C and H), and stroke plus biomaterials plus adipose stem cells (D and I), and the graph 
shows the cell count of DCX positive cells. Scale Bar: 200 μm. 




FIGURE 7. Neuroblast integration index. Graph show a data of doble- 
cortin cells express in neuroblast integration index in the vicinity of the 
lesion. The graph shows a mean T standard error. 
 
into the biomaterials. Furthermore, the implants increase the 
proliferation of neuroblasts at the SVZ. The addition of ASCs to 
the biomaterials increase the proliferative response and the 
homing effect of biomaterials, plus decreasing the astro- cytic 
reaction to stroke, implantation surgery and biomate- rials. It 
also increases the number of neurofilaments found inside the 
scaffolds and the number of newly formed vessels inside the 
biomaterials. The biomaterials are easily inte- grated into the 
core zone, and this integration was even bet- ter when ASC 
were associated (Supporting Information Figure 2). 
ASC has been used to diverse inflammatory pathologies by 
many authors; being recovery objectives not only in the 
central nervous system,25,26 ASC have shown to increase SVZ 
neurogenesis,27–31 and have antiinflammatory and cytotactic 
properties when administered in stroke models,32,33 and to 
improve function in animal models, both when administered 
locally or even through the systemic route.21,23,34,35 In addi- 
tion, it has been shown their neuroprotector effect that inter- 
venes directly in the apoptosis mechanism as describe Wei   et 
al.22,36;  and  their  secretor  effect  as  show  Cunningham  et 
al.36 However, these approaches do not seem to replace  the 
totally brain tissue lost.37,38 
Conversely, the use of scaffolds leads to true regenera- tion 
or re-formation of new cerebral tissue, not only reduc- ing the 
bulk cavitation provoked by stroke, but with the presence of 
new neurons, neurites and supporting cells and vessels, which 
might functionally integrate with the sur- rounding brain, as 
shown Fuhrmann et al., who propose the strategy of favoring 
the microenviroment.9,39–41 
Scaffolds made of HA showed compatibility with the brain, 
as previously noted.13,14 This confirms the innocuous nature of 
this biomaterial, which can be designed to fit the 
particularities of the host tissue, therefore favoring the 
migration of healthy cells adjoining the lesion zone in several 
models of injury.10,42,43 Recently, biomaterials is a growing 
sector, with very different compositions, such as plasma,  PCL, 
or hydrogels with adhered molecules. All of them share  a 
structural function to restructure the damage tissue.44–48 
The combination of HA BM+ASC has a synergistic effect, 
promotes the proliferative activity in the SVZ (increase BrdU 
and DCX positive cells), enhancing the attraction of 
 
endogenous cells, therefore, promoting an appropriate niche 
to recovery.49–51 The increase in proliferation of the SVZ 
analyzed by BrdU agrees with the increase of DCX cells in    the 
group with HA plus ASC. In the group where ASC was   not 
administered, a lower amount of DCX and a greater amount of 
GFAP is observed. So the administration of ASC and its 
immunomodulatory or anti-inflammatory effects pos- sibly 
influence the proliferation and differentiation of GFAP and 
DCX cells.23,49–51 
Furthermore, ASC increases the biocompatibility and 
homing ability of HA scaffolds.52–54 This is  done probably  by 
the antiinflammatory and cytotactic properties of ASC, but 
not by becoming part of the  final  implanted  struc-  ture, 
since no antigens marking human nuclei were found 30 days 
after implantation. Also, ASC showed a good inte- gration 
with HA when the scaffolds were preloaded with these cells, 
as shown earlier. The  combination of  the  two is safe, as no 
abnormal cell proliferation of ASC was seen neither in 
culture nor after  implantation.  Simultaneously to enhance 
an appropriate niche and the damage tissue is reduced; the 
plasticity mechanism is favored.55–57 
We used immunocompromised animals to explore safety 
in terms of possible neoplastic proliferation of ASC after 
implantation.23,48 However, these cells have not shown rejec- 
tion issues when used in immunocompetent rodent stroke 
models.36,37,58 
In control animals receiving stroke, newly formed neu- 
rons (DCX) coming from the ipsilateral SVZ were seen in the 
vicinity of the core zone, but were not seen inside the 
infarcted areas. This confirms the observations by others 
showing that stroke induces per se a repair reaction, but 
these cells are unable to stay and organize within the core 
zone.5,59 
The stroke model we used induced an infarction pattern 
which is more constant than other models.60 However,  as this 
model produces few neurological side effects in the ani- mals, 
we could not observe if this treatment strategy may produce 
functional improvement.61–63 Further studies in dif- ferent 
models should be done in rodents, or higher mammals should 
be tested to determine this. 
In conclusion, in stroke, the use of HA and ASC is novel. The 
present results show how scaffolds of HA implanted at the core 
zone of a stroke lesion permit the proliferation and migration 
of new neurons, neurites, glia, and vessels, and the addition of 
ASC increases this proliferation and  homing  effect 
(Supporting Information Figure 2). This may permit formation 
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